Results 21 to 30 of about 17,217,890 (291)

Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal.

, 2022
Clear cell renal cell carcinoma (ccRCC) is characterized by near-universal loss of the short arm of chromosome 3, deleting several tumor suppressor genes. We analyzed whole genomes from 95 biopsies across 33 patients with clear cell renal cell carcinoma.
Raine, K, Yates, LR, Teague, J, Lopez, JI, Gore, M, Rowan, A, Mitchell, TJ, Lynch, AG, Au, L, Stewart, A, Litchfield, K, Turajlic, S, Tarpey, P, Chandra, A, Csabai, I, Swanton, C, Fotiadis, N, Lynch, J, Soultati, A, Challacombe, B, Xu, H, Hazell, S, Stamp, G, Elaidi, R, Horswell, S, Campbell, PJ, Chowdhury, S, Butler, AP, Rudman, S, Wedge, DC, Futreal, PA, Nicol, D, Farmery, JHR, O'Brien, T, Maura, F, McGranahan, N, TRACERx Renal Consortium,, Spain, L, Stewart, GD, Szallasi, Z, Martincorena, I, Stares, M, Fernando, A, Larkin, J, Oudard, S, Pickering, L, Chambers, T, Angelopoulos, N   +47 more
core   +1 more source

Only three cycles of nivolumab showed remarkable durable response and reversible myeloradiculoneuropathy in a patient with metastatic papillary renal cell carcinoma type 2

IJU Case Reports, 2021
Introduction The efficacy of nivolumab for non‐clear cell renal cell carcinoma is still unclear. We present a rare case of metastatic papillary renal cell carcinoma remarkably responded to nivolumab but developed myeloradiculoneuropathy as immune‐related
Kazunori Iwasaki, Toshitaka Shin, Toru Inoue, Tadamasa Shibuya, Kenichi Hirai, Tadasuke Ando, Hiromitsu Mimata   +6 more
doaj   +1 more source

Targeted therapies and the treatment of non-clear cell renal cell carcinoma [PDF]

Annals of Oncology, 2013
Targeted therapies have shown profound effects on the outcome of patients with advanced renal cell carcinoma (RCC). However, the optimal treatment for RCC of non-clear cell histology (nccRCC)-typically excluded from trials of targeted agents-remains uncertain.By carrying out extensive searches of PubMed and ASCO databases, we identified and summarised ...
J, Bellmunt, J, Dutcher
openaire   +2 more sources

Development and validation of ferroptosis-related lncRNAs prognosis signatures in kidney renal clear cell carcinoma

Cancer Cell International, 2021
Background Ferroptosis is a recently recognised new type of cell death which may be a potential target for cancer therapy. In the present study, we aimed to screen ferroptosis-related differentially expressed long non-coding RNAs as biomarkers to predict
Xiao-Liang Xing, Zhi-Yong Yao, Jialan Ou, Chaoqun Xing, Feng Li   +4 more
doaj   +1 more source

Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome [PDF]

, 2013
Renal cell carcinoma (RCC) is the most deadly of urological malignancies. Metastatic disease affects one third of patients at diagnosis with a further third developing metastatic disease after extirpative surgery.
Antony C P Riddick, Stewart Grant D., Laird Alexander, Alexander Laird, Grant D Stewart, Laird, Alexander, O'Mahony, Fiach C, Riddick, Antony C P, Riddick Antony C. P., O’Mahony Fiach C., Harrison David J., Fiach C O'Mahony, Jyoti Nanda, Harrison, David J, David J Harrison, O'Mahony, Fiach C., Riddick, Antony C. P., Nanda Jyoti, Nanda, Jyoti, Stewart, Grant D., O’Donnell Marie, O'Donnell, Marie, Stewart, Grant D, Marie O'Donnell, Harrison, David J., Harrison, David J.; id_orcid   +25 more
core   +2 more sources

The use of automated quantitative analysis to evaluate epithelial-to-mesenchymal transition associated proteins in clear cell renal cell carcinoma [PDF]

, 2012
Background: Epithelial-to-mesenchymal transition (EMT) has recently been implicated in the initiation and progression of renal cell carcinoma (RCC). Some mRNA gene expression studies have suggested a link between the EMT phenotype and poorer clinical ...
Antony C P Riddick, Stewart Grant D., Faratian Dana, Theodoulou Marianna, Grant D Stewart, Dana Faratian (171110), O'Mahony Fiach C., O'Mahony, Fiach C, James Varley (181899), David J. Harrison (171106), Jyoti Nanda (181902), Riddick, Antony C P, Varley James, Marianna Theodoulou, Dana Faratian, Varley, James, Riddick Antony C. P., Harrison David J., Fiach C O'Mahony, Antony C. P. Riddick (145315), Jyoti Nanda, Harrison, David J, David J Harrison, O'Mahony, Fiach C., Faratian, Dana, Riddick, Antony C. P., Nanda Jyoti, Marianna Theodoulou (181905), Grant D. Stewart (145312), Theodoulou, Marianna, Nanda, Jyoti, Stewart, Grant D., James Varley, Stewart, Grant D, Fiach C. O'Mahony (181892), Harrison, David J., Harrison, David J.; id_orcid   +36 more
core   +3 more sources

Significance of chromosome 9p status in renal cell carcinoma:a systematic review and quality of the reported studies [PDF]

, 2014
Defining the prognosis of renal cell carcinoma (RCC) using genetic tests is an evolving area. The prognostic significance of 9p status in RCC, although described in the literature, remains underutilised in clinical practice. The study explored the causes
El-Mokadem, Ismail, Fitzpatrick, John, Cunningham, J., Nabi, Ghulam, Pratt, Norman, Fleming, Stewart, Rai, Bhavan   +6 more
core   +1 more source

Clear cell renal cell carcinoma molecular variations in non‐Hispanic White and Hispanic patients

Cancer Medicine, 2023
Background The United States is becoming increasingly diverse, but few molecular studies have assessed the progression of clear cell renal cell carcinoma (ccRCC) in diverse patient populations.
Ken Batai, Yuliang Chen, Brenna A. Rheinheimer, Amit Arora, Ritu Pandey, Ronald L. Heimark, Erika R. Bracamonte, Nathan A. Ellis, Benjamin R. Lee   +8 more
doaj   +1 more source

Chemotherapy-mediated p53-dependent DNA damage response in clear cell renal cell carcinoma: role of the mTORC1/2 and hypoxia-inducible factor pathways [PDF]

, 2013
The DNA-damaging agent camptothecin (CPT) and its analogs demonstrate clinical utility for the treatment of advanced solid tumors, and CPT-based nanopharmaceuticals are currently in clinical trials for advanced kidney cancer; however, little is known ...
Ashcroft, M, Carroll, VA, Selvarajah, J, Moumen, A, Nathawat, K   +4 more
core   +2 more sources

Beta-1,4-galactosyltransferase II predicts poor prognosis of patients with non-metastatic clear-cell renal cell carcinoma

Tumor Biology, 2017
Beta-1,4-galactosyltransferase II is found to be associated with the alterations of tumor-related glycosylation. However, the clinical significance of beta-1,4-galactosyltransferase II in non-metastatic clear-cell renal cell carcinoma has not been ...
Haijian Zhang, Yidong Liu, Huyang Xie, Qiang Fu, Zheng Liu, Yu Zhu, Le Xu, Weijuan Zhang, Yuanfeng Yang, Jiejie Xu   +9 more
doaj   +1 more source